TotalMarketCap

Upstream Bio

UPBNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$175.815 M

$3.21 -13.24%

Close of 6 Nov 2026

As of 6 Nov 2026, Upstream Bio (UPB) has a market capitalization of $175.8M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$2.85M

#3356 by revenue

Earnings

-$143.4M

Loss-making

Shares outstanding

54,771,041

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #253Entrada TherapeuticsTRDA$176.8M
  2. #254Natures Sunshine ProductsNATR$176.6M
  3. #255Upstream BioUPB$175.8M
  4. #256BridgeBio Oncology TherapeuticsBBOT$175.2M
  5. #257Whitehawk TherapeuticsWHWK$173.9M

What if Upstream Bio were worth as much as…

Open the what-if tool →

Gold $28.2T

$515,543.86

Per share 160,606× higher

Bitcoin $1.53T

$27,895.18

Per share 8,690× higher

Apple $5.02T

$91,577.27

Per share 28,529× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Upstream Bio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.